Effects of amantadine on behavior, respiratory chain enzymes and creatine kinase in an animal model of schizophrenia
DOI:
https://doi.org/10.12662/2317-3076jhbs.v1i1.21.p1.2013Palabras clave:
Amantadine, Schizophrenia, Creatine kinase, Respiratory chain enzymes, MitochondriaResumen
Introduction: Glutamate dysregulation may be involved in the pathophysiology of schizophrenia, and NMDA antagonists seem to be effective in its treatment. We evaluated the efficacy of amantadine (AMA) in preventing ketamine (KET)-induced effects in an animal model of schizophrenia. Methods: Adult Wistar rats received 10 mg/kg AMA for 10 days, followed by 7 days of 25 mg/kg KET ip. Thirty minutes after the last injection, rats were placed in an open-field apparatus for 60 minutes and killed by decapitation afterwards. Amygdala, hippocampus, prefrontal cortex and striatum were isolated and analyzed for creatine kinase (CK) and respiratory chain enzyme activities. Results: KET increased crossings and reduced grooming, which was not prevented by AMA. KET also increased stereotypic movements, which was partially prevented by AMA. As for CK activity, KET increased it in the prefrontal cortex, striatum and amygdala, and AMA prevented it only in prefrontal cortex and striatum. The activity of complex I was not altered by KET, however, AMA+KET increased it in the striatum and amygdala. KET increased the activity of complex II in the striatum as well, whereas AMA+KET increased it in hippocampus, prefrontal cortex, and striatum. KET did not alter complex I-III activity, whereas AMA+KET increased it in hippocampus and amygdala. AMA+KET also increased complex IV activity in hippocampus and striatum, whereas KET had no effect on this activity. Conclusion: AMA did not prevent most of KET-induced alterations. New animal models should be employed in the study of AMA as a potential novel drug for schizophrenia.
Descargas
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Autores que publican en esta revista acepta los siguientes términos:
- Autores retienen el copyright y otorguen el diario el derecho de la primera publicación, con el trabajo simultáneamente licenciado bajo la licencia Creative Commons que permite compartir el trabajo con reconocimiento de autoría y publicación inicial en este diario.
- Permite que los autores asumir contratos adicionales por separado, para su distribución no exclusiva de la obra publicada en esta versión de diario (ej.: publicar en Repositorio institucional o como un capítulo del libro), con el reconocimiento de autoría y publicación inicial en este diario.
- Autores se permite y se anima a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en tu página personal) en cualquier momento antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la citación de trabajos publicados (ver el efecto del acceso abierto).